1681.HK लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 13:38):

Stats
आज की मात्रा	1.17M
औसत मात्रा	786 395
बाजार मूल्य	5.00B
EPS	HKD0 ( 2024-03-28 )
अगली कमाई की तारीख	( HKD0 ) 2024-05-31
Last Dividend	HKD0.300 ( 2023-06-08 )
Next Dividend	HKD0 ( N/A )
P/E	5.90
ATR14	HKD0.00700 (0.11%)

मात्रा सहसंबंध

लंबा: -0.23 (neutral)

छोटा: 0.55 (weak)

Signal:(49.449) Neutral

Consun Pharmaceutical सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Consun Pharmaceutical सहसंबंध - मुद्रा/वस्त्र

0.02
( neutral )

-0.01
( neutral )

0.00
( neutral )

0.30
( neutral )

0.68
( moderate )

0.04
( neutral )

Consun Pharmaceutical वित्तीय

Annual	2023
राजस्व:	HKD2.59B
सकल लाभ:	HKD1.92B (74.19 %)
EPS:	HKD0.990

FY	2023
राजस्व:	HKD2.59B
सकल लाभ:	HKD1.92B (74.19 %)
EPS:	HKD0.990

FY	2022
राजस्व:	HKD2.34B
सकल लाभ:	HKD1.76B (75.35 %)
EPS:	HKD0.860

FY	2021
राजस्व:	HKD2.04B
सकल लाभ:	HKD1.53B (74.70 %)
EPS:	HKD0.740

Financial Reports:

No articles found.

Consun Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.300 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Consun Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.45 - good (84.50%) | Divividend Growth Potential Score: 5.71 - Stable (14.27%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0480	2014-09-25
Last Dividend	HKD0.300	2023-06-08
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	19	--
Total Paid Out	HKD2.25	--
Avg. Dividend % Per Year	0.00%	--
Score	3.31	--
Div. Sustainability Score	8.45
Div.Growth Potential Score	5.71
Div. Directional Score	7.08	--

Next Divdend (Est)
(2024-06-24)

HKD0.334 Estimate 3.45 %

Dividend Stability

0.28 Very Poor

Dividend Score

3.31

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2270.HK	Ex Dividend Junior	2023-06-26	Insufficient data to determine frequency	0.00%
1258.HK	Ex Dividend Knight	2023-06-30	Annually	0.00%
0315.HK	Ex Dividend Knight	2023-11-06	Semi-Annually	0.00%
6049.HK	Ex Dividend Knight	2023-06-08	Annually	0.00%
1816.HK	Ex Dividend Junior	2023-05-30	Annually	0.00%
0842.HK	Ex Dividend Junior	2023-09-04	Sporadic	0.00%
0002.HK	Ex Dividend Knight	2023-09-04	Quarterly	0.00%
2588.HK	Ex Dividend Knight	2023-09-25	Semi-Annually	0.00%
1381.HK	Ex Dividend Knight	2023-09-11	Semi-Annually	0.00%
0440.HK	Ex Dividend Knight	2023-09-07	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.303	1.500	3.94	5.91	[0 - 0.5]
returnOnAssetsTTM	0.142	1.200	5.25	6.30	[0 - 0.3]
returnOnEquityTTM	0.227	1.500	8.59	10.00	[0.1 - 1]
payoutRatioTTM	0.416	-1.000	5.84	-5.84	[0 - 1]
currentRatioTTM	2.86	0.800	0.692	0.554	[1 - 3]
quickRatioTTM	2.57	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.838	1.500	0.898	1.347	[0.2 - 2]
debtRatioTTM	0.0929	-1.500	8.45	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	1.018	2.00	9.66	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.953	2.00	9.52	10.00	[0 - 20]
debtEquityRatioTTM	0.141	-1.500	9.44	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.742	1.000	0.968	0.968	[0.2 - 0.8]
operatingProfitMarginTTM	0.319	1.000	5.62	5.62	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.601	1.000	2.22	2.22	[0.2 - 2]
assetTurnoverTTM	0.470	0.800	-0.198	-0.159	[0.5 - 2]
Total Score				8.45

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	5.69	1.000	9.53	0	[1 - 100]
returnOnEquityTTM	0.227	2.50	9.10	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.953	2.00	9.68	10.00	[0 - 30]
dividendYielPercentageTTM	8.11	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.018	2.00	9.66	10.00	[0 - 30]
payoutRatioTTM	0.416	1.500	5.84	-5.84	[0 - 1]
pegRatioTTM	-0.0747	1.500	-3.83	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.316	1.000	4.60	0	[0.1 - 0.5]
Total Score				5.71

Consun Pharmaceutical

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.